INJECTABLES

Sterile Ceftriaxone 1000mg + Sterile Tazobactam125 mg
Item Code : ADEONE TAZ
Special Precautions:
History of penicillin allergy; lactation. Consider possibility of pseudomembranous colitis in patients who present with diarrhoea subsequent to the admin of antibacterial agents. Monitor prothrombin time in patients with impaired vit K synthesis or low vit K stores during treatment. Prolonged treatment may result in overgrowth of nonsusceptible organisms. Caution in patients with a history of GI disease, especially colitis.Discontinue treatment in patients who develop signs/symptoms suggestive of gallbladder disease. Not to be used in hyperbilirubinemic neonates, especially prematures.
Dosage:
Intravenous
Skin and skin structure infections, Bacterial septicaemia, Urinary tract infections, Lower respiratory tract infections, Intra-abdominal infections, Bacterial meningitis, Bone and joint infections, Community-acquired pneumonia, Uncomplicated gonorrhoea, Pelvic inflammatory disease
Adult: Expressed in terms of ceftriazone/tazobactam: 1000/125 mg once daily or in equally divided doses twice a day. Total daily dose should not exceed 4 g of ceftriaxone. Continue treatment for at least 2 days after the signs and symptoms have resolved. Usual duration: 7-14 days; longer treatment may be needed in more serious infections. For Streptococci pyogenes infections, treatment should continue for at least 10 days.
Child: Expressed in terms of ceftriaxone: Serious infections: 50-75 mg/kg/day, given in divided doses every 12 hours. Total daily dose should not exceed 2 g of ceftriaxone. Continue treatment for at least 2 days after the signs and symptoms have resolved. Usual duration: 7-14 days; longer treatment may be needed in more serious infections. For Streptococci pyogenes infections, treatment should continue for at least 10 days.
Incompatibility
Vancomycin and fluconazole are incompatible with ceftriaxone in admixture.
Storage:
Intravenous
Before reconstitution: Store below 25°C
Ceftriaxone 250 mg Injection
Item Code:ADEONE-250
Ceftriaxone sodium is a white to yellowish-orange crystalline powder which is readily soluble in water, sparingly soluble in methanol and very slightly soluble in ethanol. The pH of a 1% aqueous solution is approximately 6.7. The color of ceftriaxone for injection, USP solutions ranges from light yellow to amber, depending on the length of storage, concentration and diluent used. Ceftriaxone for injection contains approximately 83 mg (3.6 mEq) of sodium per gram of ceftriaxone activity.
PRECAUTIONS:
General
Prescribing ceftriaxone for injection, USP in the absence of a proven or strongly suspected bacterial infection or a prophylactic indication is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria. Although transient elevations of BUN and serum creatinine have been observed, at the recommended dosages, the nephrotoxic potential of ceftriaxone is similar to that of other cephalosporins. Ceftriaxone is excreted via both biliary and renal excretion. Therefore, patients with renal failure normally require no adjustment in dosage when usual doses of ceftriaxone are administered, but concentrations of drug in the serum should be monitored periodically. If evidence of accumulation exists, dosage should be decreased accordingly. Dosage adjustments should not be necessary in patients with hepatic dysfunction; however, in patients with both hepatic dysfunction and significant renal disease, ceftriaxone dosage should not exceed 2 g daily without close monitoring of serum concentrations. Alterations in prothrombin times have occurred rarely in patients treated with ceftriaxone. Patients with impaired vitamin K synthesis or low vitamin K stores (e.g., chronic hepatic disease and malnutrition) may require monitoring of prothrombin time during ceftriaxone treatment. Vitamin K administration (10 mg weekly) may be necessary if the prothrombin time is prolonged before or during therapy. Prolonged use of ceftriaxone may result in overgrowth of nonsusceptible organisms. Careful observation of the patient is essential. If superinfection occurs during therapy, appropriate measures should be taken. Ceftriaxone should be prescribed with caution in individuals with a history of gastrointestinal disease, especially colitis.
Dosage:
ADULTS
The usual adult daily dose is 1 to 2 grams given once a day (or in equally divided doses twice a day) depending on the type and severity of infection. The total daily dose should not exceed 4 grams.
If Chlamydia trachomatis is a suspected pathogen, appropriate antichlamydial coverage should be added, because ceftriaxone sodium has no activity against this organism.
For the treatment of uncomplicated gonococcal infections, a single intramuscular dose of 250 mg is recommended.
For preoperative use (surgical prophylaxis), a single dose of 1 gram administered intravenously 1/2 to 2 hours before surgery is recommended.
Generally, ceftriaxone for injection therapy should be continued for at least 2 days after the signs and symptoms of infection have disappeared. The usual duration of therapy is 4 to 14 days; in complicated infections, longer therapy may be required.
When treating infections caused by Streptococcus pyogenes, therapy should be continued for at least 10 days.
NEONATES
Hyperbilirubinemic neonates, especially prematures, should not be treated with ceftriaxone (see CONTRAINDICATIONS).
Ceftriaxone is contraindicated in neonates if they require (or are expected to require) treatment with calcium-containing IV solutions, including continuous calcium-containing infusions such as parenteral nutrition because of the risk of precipitation of ceftriaxone-calcium (see CONTRAINDICATIONS).
PEDIATRIC PATIENTS
For the treatment of skin and skin structure infections, the recommended total daily dose is 50 to 75 mg/kg given once a day (or in equally divided doses twice a day). The total daily dose should not exceed 2 grams.
For the treatment of serious miscellaneous infections other than meningitis, the recommended total daily dose is 50 to 75 mg/kg, given in divided doses every 12 hours. The total daily dose should not exceed 2 grams.
In the treatment of meningitis, it is recommended that the initial therapeutic dose be 100 mg/kg (not to exceed 4 grams). Thereafter, a total daily dose of 100 mg/kg/day (not to exceed 4 grams daily) is recommended. The daily dose may be administered once a day (or in equally divided doses every 12 hours). The usual duration of therapy is 7 to 14 days.
Patients with impairment of renal or hepatic function
No dosage adjustment is necessary for patients with impairment of renal or hepatic function; however, blood levels should be monitored in patients with severe renal impairment (e.g., dialysis patients) and in patients with both renal and hepatic dysfunctions.
Dosage:
As prescribed by doctor. Storage:
Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature]. Protect from light.
Ceftriaxone 500 mg Injection
Item Code: ADEONE-500
Ceftriaxone is a cephalosporin antibiotic. It works by interfering with the formation of the bacteria's cell wall so that the wall ruptures, resulting in the death of the bacteria.
Precautions:
This drug is contraindicated in premature neonates up to postmenstrual age of 41 weeks (gestational age + chronological age); this drug is not recommended for use in hyperbilirubinemic neonates.
Dosage:
As prescribed by doctor. Storage:
Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature]. Protect from light.
Ceftriaxone 1000 mg Injection
Item Code: ADEONE-1K
Ceftriaxone for injection USP is a sterile, semisynthetic, broad-spectrum cephalosporin antibiotic for intravenous or intramuscular administration. Ceftriaxone sodium is (6R,7R) - 7 - [2 - (2 - Amino - 4 - thiazolyl)glyoxylamido] - 8 - oxo - 3 - [[(1,2,5,6 - tetrahydro - 2 - methyl - 5,6 - dioxo - as-triazin-3-yl)thio]methyl]-5-thia-1-azabicyclo [4.2.0]oct-2-ene-2-carboxylic acid, 72-(Z)-(O-methyloxime), disodium salt, sesquaterhydrate.
Precautions:
General
Development of Drug-resistant Bacteria
Prescribing Ceftriaxone for injection in the absence of a proven or strongly suspected bacterial infection or a prophylactic indication is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria. Prolonged use of Ceftriaxone for injection may result in overgrowth of nonsusceptible organisms. Careful observation of the patient is essential. If superinfection occurs during therapy, appropriate measures should be taken.
Patients with Renal or Hepatic Impairment
Ceftriaxone is excreted via both biliary and renal excretion (see CLINICAL PHARMACOLOGY). Therefore, patients with renal failure normally require no adjustment in dosage when usual doses of Ceftriaxone for injection are administered.
Dosage adjustments should not be necessary in patients with hepatic dysfunction; however, in patients with both hepatic dysfunction and significant renal disease, caution should be exercised and the Ceftriaxone for injection dosage should not exceed 2 gm daily.
Ceftriaxone is not removed by peritoneal- or hemodialysis. In patients undergoing dialysis no additional supplementary dosing is required following the dialysis. In patients with both severe renal and hepatic dysfunction, close clinical monitoring for safety and efficacy is advised.
Effect on Prothrombin Time
Alterations in prothrombin times have occurred in patients treated with Ceftriaxone for injection. Monitor prothrombin time during Ceftriaxone for injection treatment in patients with impaired vitamin K synthesis or low vitamin K stores (eg, chronic hepatic disease and malnutrition). Vitamin K administration (10 mg weekly) may be necessary if the prothrombin time is prolonged before or during therapy.
Concomitant use of Ceftriaxone with Vitamin K antagonists may increase the risk of bleeding. Coagulation parameters should be monitored frequently, and the dose of the anticoagulant adjusted accordingly, both during and after treatment with Ceftriaxone (see ADVERSE REACTIONS).
Gallbladder Pseudolithiasis
Ceftriaxone-calcium precipitates in the gallbladder have been observed in patients receiving Ceftriaxone FOR INJECTION. These precipitates appear on sonography as an echo without acoustical shadowing suggesting sludge or as an echo with acoustical shadowing which may be misinterpreted as gallstones. The probability of such precipitates appears to be greatest in pediatric patients. Patients may be asymptomatic or may develop symptoms of gallbladder disease. The condition appears to be reversible upon discontinuation of Ceftriaxone sodium and institution of conservative management. Discontinue Ceftriaxone sodium in patients who develop signs and symptoms suggestive of gallbladder disease and/or the sonographic findings described above.
Urolithiasis and Post-Renal Acute Renal Failure
Ceftriaxone-calcium precipitates in the urinary tract have been observed in patients receiving Ceftriaxone FOR INJECTION and may be detected as sonographic abnormalities. The probability of such precipitates appears to be greatest in pediatric patients. Patients may be asymptomatic or may develop symptoms of urolithiasis, and ureteral obstruction and post-renal acute renal failure. The condition appears to be reversible upon discontinuation of Ceftriaxone sodium and institution of appropriate management. Ensure adequate hydration in patients receiving Ceftriaxone FOR INJECTION. Discontinue Ceftriaxone FOR INJECTION in patients who develop signs and symptoms suggestive of urolithiasis, oliguria or renal failure and/or the sonographic findings described above.
Pancreatitis
Cases of pancreatitis, possibly secondary to biliary obstruction, have been reported in patients treated with Ceftriaxone for injection. Most patients presented with risk factors for biliary stasis and biliary sludge (preceding major therapy, severe illness, total parenteral nutrition). A cofactor role of Ceftriaxone for injection -related biliary precipitation cannot be ruled out.
Dosage:
Neonates
Hyperbilirubinemic neonates, especially prematures, should not be treated with Ceftriaxone for injection. Ceftriaxone for injection is contraindicated in premature neonates (see CONTRAINDICATIONS).
Ceftriaxone for injection is contraindicated in neonates (≤ 28 days) if they require (or are expected to require) treatment with calcium-containing IV solutions, including continuous calcium- containing infusions such as parenteral nutrition because of the risk of precipitation of Ceftriaxone-calcium (see CONTRAINDICATIONS).
Intravenous doses should be given over 60 minutes in neonates to reduce the risk of bilirubin encephalopathy.
Pediatric Patients
For the treatment of skin and skin structure infections, the recommended total daily dose is 50 to 75 mg/kg given once a day (or in equally divided doses twice a day). The total daily dose should not exceed 2 grams.
For the treatment of acute bacterial otitis media, a single intramuscular dose of 50 mg/kg (not to exceed 1 gram) is recommended (see INDICATIONS AND USAGE).
For the treatment of serious miscellaneous infections other than meningitis, the recommended total daily dose is 50 to 75 mg/kg, given in divided doses every 12 hours. The total daily dose should not exceed 2 grams.
In the treatment of meningitis, it is recommended that the initial therapeutic dose be 100 mg/kg (not to exceed 4 grams). Thereafter, a total daily dose of 100 mg/kg/day (not to exceed 4 grams daily) is recommended. The daily dose may be administered once a day (or in equally divided doses every 12 hours). The usual duration of therapy is 7 to 14 days.
Adults
The usual adult daily dose is 1 to 2 grams given once a day (or in equally divided doses twice a day) depending on the type and severity of infection. The total daily dose should not exceed 4 grams.
If Chlamydia trachomatis is a suspected pathogen, appropriate antichlamydial coverage should be added, because Ceftriaxone sodium has no activity against this organism.
For the treatment of uncomplicated gonococcal infections, a single intramuscular dose of 250 mg is recommended.
For preoperative use (surgical prophylaxis), a single dose of 1 gram administered intravenously 1/2 to 2 hours before surgery is recommended.
Generally, Ceftriaxone for injection therapy should be continued for at least 2 days after the signs and symptoms of infection have disappeared. The usual duration of therapy is 4 to 14 days; in complicated infections, longer therapy may be required.
When treating infections caused by Streptococcus pyogenes, therapy should be continued for at least 10 days.
Storage:
Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature]. Protect from light.
Ceftriaxone 500 Mg & Salbactum 250 Mg Injection
Item Code: ADEONE-S
Ceftriaxone is a broad-spectrum semi-synthetic third-generation cephalosporin with a potent bactericidal activity against a wide range of gram-positive and gram-negative bacteria. Sulbactam is ß– lactamase inhibitor.
Dosage:
The recommended adult dosage is 1.5 g (1 g Ceftriaxone as the sodium salt plus 0.5 g sulbactam as the sodium salt) to 3 g (2 g Ceftriaxone as the sodium salt plus 1 g sulbactam as the sodium salt) every six hours. This 1.5 to 3 g range represents the total of Ceftriaxone content plus the sulbactam content and corresponds to a range of 1 g Ceftriaxone /0.5 g sulbactam to 2 g Ceftriaxone /1 g sulbactam. The total dose of sulbactam should not exceed 4 grams per day.
Neonates, infants and children up to 12 years:
The following dosage schedules are recommended for once daily administration. Neonates (up to 14 days): 20 to 50 mg/kg bodyweight once daily. The daily dose should not exceed 50 mg/kg. It is not necessary to differentiate between premature and term infants. Infants and children (15 days to 12 years): 20 to 80 mg/kg once daily. For children with bodyweights of 50 kg or more, the usual adult dosage should be used. Intravenous doses of NLT 50 mg/kg bodyweight should be given by infusion over at least 30 minutes.
Ceftriaxone 1000 Mg & Salbactum 500 Mg Injection
Item Code: ADEONE-SPLUS
Ceftriaxone is a broad-spectrum semi-synthetic third-generation cephalosporin with a potent bactericidal activity against a wide range of gram-positive and gram-negative bacteria. Sulbactam is ß– lactamase inhibitor.
Dosage:
The recommended adult dosage is 1.5 g (1 g Ceftriaxone as the sodium salt plus 0.5 g sulbactam as the sodium salt) to 3 g (2 g Ceftriaxone as the sodium salt plus 1 g sulbactam as the sodium salt) every six hours. This 1.5 to 3 g range represents the total of Ceftriaxone content plus the sulbactam content and corresponds to a range of 1 g Ceftriaxone /0.5 g sulbactam to 2 g Ceftriaxone /1 g sulbactam. The total dose of sulbactam should not exceed 4 grams per day.
Neonates, infants and children up to 12 years:
The following dosage schedules are recommended for once daily administration. Neonates (up to 14 days): 20 to 50 mg/kg bodyweight once daily. The daily dose should not exceed 50 mg/kg. It is not necessary to differentiate between premature and term infants. Infants and children (15 days to 12 years): 20 to 80 mg/kg once daily. For children with bodyweights of 50 kg or more, the usual adult dosage should be used. Intravenous doses of NLT 50 mg/kg bodyweight should be given by infusion over at least 30 minutes.
Diclofenac Sodium 75 mg/ml Aqueous Injection
Item Code : KILACHE-INJ
Precautions:
Patients suffering from impairment of hepatic, cardiac, or renal function should be carefully monitored.
Dosage may have to be reduces in the elderly.
In view of the product's inherent potential to cause fluid retention, heart failure may be precipitated in some compromised patients.
During prolonged treatment with Acu-diclofenac injection blood counts and monitoring of hepatic and renal function are indicated as precautionary measures.
Special Precautions:
Patients may complain of nausea and diarrhoea, headache, tinnitus or dizziness. Peripheral oedema and skin reactions, such as drug rash and eczema, have also been encountered. Central nervous system side-effects, such as tiredness, insomnia, nervousness, depression or irritability, have occurred. Blurred vision and other ocular reactions.
Sensitivity reactions (e.g. bronchospasm, anaphylactic/anaphylactoid systemic reactions), elevated transaminase levels, jaundice, hepatitis, renal failure and nephrotic syndrome, may occur. Dyshaemopoiesis (leucopenia, thrombocytopenia, aplastic anaemia) and erythema multiforme have been observed. Agranulocytosis and haemolytic anaemia have been observed. Abscesses and local necrosis have also occurred, particularly in elderly diabetics.
Dosage:
Not intended for intravenous route administration. For adults the dosage is generally one Acu-diclofenac injection daily, injected deep intragluteally into the upper outer quadrant. By way of exception, in severe cases two injections, separated by an interval of a few hours, can be given per day (one into each buttock). Acu-diclofenac injection should not be given for more than a few days.
Storage:
Store below 25°C. Protect from light. KEEP OUT OF REACH OF CHILDREN.
Methylcobalamin 1500 Mcg Injection
Item Code: MECODEPT-INJ
Methylcobalamin is a cobalamin (MeB12) used in peripheral neuropathy, diabetic neuropathy etc. It is a form of vitamin B12. This vitamer is one of two active coenzymes used by B-12 dependent enzymes in the body, and is specifically the B-12 form used by 5-methyltetrahydrofolate-homocysteine methyltransferase (MTR), also known as methionine synthase.
Methylcobalamin is notable for being one of the few examples in nature of a bona fide organometallic bond. Methylcobalamin has been studied in conjunction with sleep-wake rhythm disorders, where it appears to yield benefits, but at a low or inconsistent level. It is used in treating diseases of vitamin B12 deficiency (such as pernicious anemia), or diseases of effective B12 deficiency, such as vitamin B12 metabolic pathway pathologies. One study suggests that once absorbed, methylcobalamin may be retained in the body better than cyanocobalamin.
Dosage:
Oral
Peripheral neuropathies Adult: 1500 mcg/day in 3 divided doses.
Parenteral
Peripheral neuropathies Adult: 500 mcg daily IM/IV 3 times/wk.
Parenteral
Megaloblastic anaemia caused by vitamin B12 deficiency Adult: 500 mcg daily IM/IV 3 times/wk. Maintenance dose: After about 2 mth of therapy, reduce dose to single admin of 500 mcg every 1-3 mth.
Storage:
Oral
Store at room temperature. Protect from moisture and light. Parenteral: Store at room temperature. Do not expose to direct light.
Pantoprazole Sodium 40 mg Injection
Item Code: PETOZOLE-INJ
Pantoprazole (Sold as Pantotab; Pantopan; Protium; Protonix; Pantozol; Pantor; Pantoloc; Astropan; Controloc; Pantecta; Inipomp; Somac; Ulcepraz; Pantodac) is a proton pump inhibitor drug used for short-term treatment of erosion and ulceration of the esophagus caused by gastroesophageal reflux disease. Initial treatment is generally of eight weeks' duration, after which another eight week course of treatment may be considered if necessary. It can be used as a maintenance therapy for long term use after initial response is obtained. This medication may affect the results of certain lab tests, such as drug screenings (pantoprazole can cause a false positive for THC). It is recommended you make sure laboratory personnel and your doctor know you are using this drug. The active ingredient in Protonix (pantoprazole sodium). Delayed-Release Tablets is a substituted benzimidazole,sodium 5-(difluoromethoxy)-2-[[(3,4-dimethoxy-2-pyridinyl)methyl] sulfinyl]-1 H -benzimidazole sesquihydrate, a compound that inhibits gastric acid secretion
Special Precautions:
Long-term therapy may lead to bacterial overgrowth in the GI tract. Hepatic impairment; monitor liver function regularly (if enzymes increase, discontinue); pregnancy; not recommended in children <18 yr; long term use may lead to atrophic gastritis.
Dosage:
Oral
Gastro-oesophageal reflux disease
Adult: 20-40 mg once daily in the morning for 4 wk, increased to 8 wk if necessary. Maintenance: 20-40 mg daily, increased to 40 mg each morning if symptoms return.
Hepatic impairment: Doses >40 mg daily have not been studied in hepatically-impaired patients.
Oral
Peptic ulcer
Adult: 40 mg once daily in the morning for 2-4 wk for duodenal ulceration or 4-8 wk for benign gastric ulceration.
Hepatic impairment: Doses >40 mg daily have not been studied in hepatically-impaired patients.
Oral
H.pylori infection
Adult: Triple therapy: 40 mg bid combined with clarithromycin 500 mg bid and either amoxicillin 1 g bid or metronidazole 400 mg bid.
Hepatic impairment: Doses >40 mg daily have not been studied in hepatically-impaired patients.
Oral
Prevention of NSAID-induced ulcers
Adult: 20 mg daily.
Hepatic impairment: Doses >40 mg daily have not been studied in hepatically-impaired patients.
Oral
Zollinger-Ellison syndrome
Adult: Initially 80 mg daily, adjusted to individual requirements. Up to 240 mg daily may be used if needed. Daily doses >80 mg should be given in 2 divided doses.
Hepatic impairment: Doses >40 mg daily have not been studied in hepatically-impaired patients.
Intravenous
Zollinger-Ellison syndrome
Adult: As Na salt: 80 mg once or twice daily. Up to 240 mg daily may be given in divided doses. Convert to oral therapy as soon as possible. Dose to be given as slow inj or short-term infusion over 2-15 minutes.
Hepatic impairment: May need to reduce dose.
Intravenous
Gastro-oesophageal reflux disease
Adult: As Na salt: 40 mg daily. Convert to oral therapy as soon as possible. Dose to be given as slow inj or short-term infusion over 2-15 minutes.
Hepatic impairment: May need to reduce doses.
Intravenous
Peptic ulcer
Adult: As Na salt: 40 mg daily. Convert to oral therapy as soon as possible. Dose to be given as slow inj or short-term infusion over 2-15 minutes.
Hepatic impairment: May need to reduce doses.
Reconstitution
Reconstitute with 10 ml 0.9% sodium chloride (final concentration 4 mg/ml). Reconstituted solution may be given IV (over 2 minutes) or diluted to 100 ml in glucose 5%, 0.9% sodium chloride, or lactated Ringer's and infused over 15 min.
Incompatibility
Y site incompatibility: midazolam and zinc.
Storage:
Intravenous
IV (before reconstitution) <25 °C.
Once reconstituted, store <25 °C and use within 12 hours.
Oral
Store tablet at 15-30 °C.
Artinsunate 60 mg Injection
Item Code : ARTIDEPT
Artesunate (INN) is part of the artemisinin group of drugs that treat malaria. It is a semi-synthetic derivative of artemisinin that is water-soluble and may therefore be given by injection. It is sometimes abbreviated AS.
Special Precautions:
Hepatic or renal insufficiency. Pregnancy and lactation. Dosage:
Parenteral
Falciparum malaria
Adult: 2.4 mg/kg via IM or IV admin. Repeat 12 hr and 24 hr later, then once daily thereafter.
Child: 2.4 mg/kg via IM or IV admin. Repeat 12 hr and 24 hr later, then once daily thereafter.
Meropenem 1000 mg Injection
Item Code : MERODEPT 1G
Meropenem, an antibiotic is prescribed for the treatment of intra-abdominal infections including appendicitis, peritonitis, bacterial meningitis, nosocomial pneumonia (hospital-acquired), skin and soft tissue infections in adults and children.
Precautions:
Meropenem should be administered to patients with allergy to Penicillin antibiotics, Cephalosporin, Imipenem and Meropenem. Meropenem is contraindicated in patients with renal diseases, brain tumor, head injury and seizures. An adjusted dosage may be needed in such patients.
Special Precautions:
History of hypersensitivity to carbapenem, pencillins or other β-lactam antibiotics; infants <3 months; renal insufficiency; neurological disorders; pregnancy, lactation. Not recommended for use in MRSA.
Dosage:
For Intra-abdominal Infection (Adults):
Administer 1 g of Meropenem, IV, thrice daily for 7 to 14 days.
For Meningitis (Adults):
Administer 1-2 g of Meropenem, IV, thrice daily for 7 to 21 days
For Nosocomial Pneumonia (Adults):
Administer 1 gm of Meropenem, IV, every 8 hours. Empirical therapy with broad-spectrum antibiotics and on antibiogram is recommended in multi-drug resistant infections. In Pseudomonas aeruginosa negative infections, the treatment should be restricted to less than 7 days.
For Skin or Soft Tissue Infection (Adults):
For complication infections, administer 500 mg IV, every 8 hours. The treatment should be continued for at least 7-10 days or for three days after the onset of inflammation. In case of severe infections including diabetic soft tissue infections, 14-21 days treatment should be considered.
For Intra-abdominal Infection (Pediatric):
For children 3 months and older, consider administration of 20 mg/kg Meropenem, IV, every 8 hours. The maximum dose should not exceed 3 g/day. For children with body weight 50 kg and over, 1 g of Meropenem should be administered intravenously every 8 hours.
For Meningitis (Pediatric):
For children 3 months and older, consider administration of 40 mg/kg Meropenem, IV, every 8 hours. The maximum dose should not exceed 6 g/day. For children with body weight 50 kg and over, 2 g of Meropenem should be administered intravenously every 8 hours.
For Complicated Skin and Structure Infection (Pediatric):
For children 3 months and older, consider administration of 10 mg/kg Meropenem, IV, every 8 hours. The maximum dose should not exceed 1.5 g/day. For children with body weight 50 kg and over, 500 mg of Meropenem should be administered intravenously every 8 hours.

Storage:
Store at 20-25°C.
Nandrolone Decanoate 25 mg Injection
Item Code: NANODEPT 25
Nandrolone (19-nortestosterone) is an anabolic steroid that may be present naturally in the human body, albeit in minute quantities of less than 0.4 ng/ml. Nandrolone is most commonly sold commercially as its decanoate ester (Deca-Durabolin) and less commonly as a phenylpropionate ester (Durabolin). Nandrolone decanoate is used in the treatment of osteoporosis in postmenopausal women (though now not recommended) at a dose of 50 mg every three weeks. It is also used for some aplastic anaemias.
Precautions:
Women should be observed for signs of virilization (deepening of the voice, hirsutism, acne, clitorimegaly and menstrual irregularities). Discontinuation of drug therapy at the time of evidence of mild virilism is necessary to prevent irreversible virilization. Such virilization is usual following anabolic steroid use in high doses.
The insulin or oral hypoglycemic dosage may need adjustment in diabetic patients who receive anabolic steroids.
Special Precautions: Monitor diabetic patients carefully. Conditions influenced by oedema (e.g. CV disease, migraine, seizure disorder, renal impairment). Hepatic impairment. Elderly. Discontinue if signs of virilisation in women occur. Monitor skeletal maturation in children.
Dosage:
Intramuscular
As anabolic after debilitating illness
Adult: As decanoate: 25-100 mg once every 3-4 weeks.
Intramuscular
Postmenopausal osteoporosis
Adult: As decanoate: 25-100 mg once every 3-4 weeks.
Intramuscular
Metastatic breast cancer
Adult: As decanoate: 25-100 mg once every 3-4 weeks.
Intramuscular
Anaemia of chronic renal failure
Adult: As decanoate: 50-200 mg weekly.
Intramuscular
Anaemia in chemotherapy patients
Adult: 50-150 mg weekly.
Nandrolone Decanoate 50 mg Injection
Item Code:NANODEPT 50
Nandrolone (19-nortestosterone) is an anabolic steroid that may be present naturally in the human body, albeit in minute quantities of less than 0.4 ng/ml. Nandrolone is most commonly sold commercially as its decanoate ester (Deca-Durabolin) and less commonly as a phenylpropionate ester (Durabolin). Nandrolone decanoate is used in the treatment of osteoporosis in postmenopausal women (though now not recommended) at a dose of 50 mg every three weeks. It is also used for some aplastic anaemias.
Precautions:
Women should be observed for signs of virilization (deepening of the voice, hirsutism, acne, clitorimegaly and menstrual irregularities). Discontinuation of drug therapy at the time of evidence of mild virilism is necessary to prevent irreversible virilization. Such virilization is usual following anabolic steroid use in high doses.
The insulin or oral hypoglycemic dosage may need adjustment in diabetic patients who receive anabolic steroids.
Special Precautions: Monitor diabetic patients carefully. Conditions influenced by oedema (e.g. CV disease, migraine, seizure disorder, renal impairment). Hepatic impairment. Elderly. Discontinue if signs of virilisation in women occur. Monitor skeletal maturation in children.
Dosage:
Intramuscular
As anabolic after debilitating illness
Adult: As decanoate: 25-100 mg once every 3-4 weeks.
Intramuscular
Postmenopausal osteoporosis
Adult: As decanoate: 25-100 mg once every 3-4 weeks.
Intramuscular
Metastatic breast cancer
Adult: As decanoate: 25-100 mg once every 3-4 weeks.
Intramuscular
Anaemia of chronic renal failure
Adult: As decanoate: 50-200 mg weekly.
Intramuscular
Anaemia in chemotherapy patients
Adult: 50-150 mg weekly.
Piperacillin 4000 mg, Sterile Tazobactam 500 mg Injection
Item Code:PEPONE TAZ
Piperacillin/Tazobactam is a combination antibiotic containing the extended-spectrum penicillin antibiotic piperacillin and the β-lactamase inhibitor tazobactam. It has an antimicrobial activity against a wide range of gm-ve organisms including K. pneumoniae, P. aeruginosa, Enterobacteriaceae and against gm+ve organisms eg E. faecalis and B. fragilis. Tazobactam is a penicillanic acid sulfone derivative with beta-lactamase inhibitory properties. In combination, tazobactam enhances the activity of piperacillin against beta-lactamase-producing bacteria.
Special Precautions:
Pregnancy and lactation, pseudomembranous colitis. Assess hematopoietic function periodically. Perform periodic electrolyte determinations in patients with low K reserves. Increased risk of fever and rash in patients with cystic fibrosis. Increased risk of bleeding manifestations.Prolonged treatment may increase risk of superinfections. Convulsions or neuromuscular excitability may occur when high doses are used, especially in renally impaired patients. Renal impairment.
Dosage:
Adult: Initial dose: 4.5 g (piperacillin 4 g and tazobactam 0.5 g) every 6 hours for 7-14 days. When used empirically, combination with an aminoglycoside or antipseudomonal fluoroquinolone is recommended. May be given via infusion over 30 minutes. If Pseudomonas aeruginosa is not isolated, may discontinue aminoglycoside.
Child: 2-8 months: 80 mg of piperacillin/kg every 8 hours; ≥9 month and ≤40 kg: 100 mg of piperacillin/kg every 8 hours.
Renal impairment: For haemodialysis: admin an additional dose of 0.75 g after each dialysis session on hemodialysis days.
CrCl (ml/min) Dosage Recommendation
20-40 3.375 g every 6 hours
<20 2.25 g every 6 hours
Haemodialysis 2.25 g every 8 hours
CAPD 2.25 g every 8 hours
Intravenous
Severe infections
Adult: 3.375 g (piperacillin 3 g and tazobactam 0.375 g) every 6 hours for 7-10 days. May be given via infusion over 30 minutes.
Renal impairment: For haemodialysis, admin an additional dose of 0.75 g after each dialysis session on haemodialysis days.
CrCl (ml/min) Dosage Recommendation
>40 3.375 g every 6 hours
20-40 2.25 g every 6 hours
<20 2.25 g every 8 hours
Haemodialysis 2.25 g every 12 hours
CAPD 2.25 g every 12 hours
Incompatibility
Not compatible with tobramycin for simultaneous admin via Y-site infusion.
Storage:
Intravenous
Injection vials should be stored at 20-25°C prior to reconstitution
Ondanstrone Hcl 2 mg Injection / 2 ml
Item Code:VOMEGO
The active ingredient in Ondansetron Injection and Ondansetron Injection Premixed is ondansetron hydrochloride (HCl), the racemic form of ondansetron and a selective blocking agent of the serotonin 5-HT3 receptor type. Chemically it is (±) 1, 2, 3, 9-tetrahydro-9-methyl-3-[(2-methyl-1H-imidazol-1-yl)methyl]-4H-carbazol-4-one, monohydrochloride, dihydrate. The empirical formula is C18H19N3O•HCl•2H2O, representing a molecular weight of 365.9. Ondansetron HCl is a white to off-white powder that is soluble in water and normal saline.
Precautions:
Hypersensitivity Reactions
Hypersensitivity reactions, including anaphylaxis and bronchospasm, have been reported in patients who have exhibited hypersensitivity to other selective 5-HT3 receptor antagonists.
QT Prolongation
Ondansetron prolongs the QT interval in a dose-dependent manner. In addition, post-marketing cases of Torsade de Pointes have been reported in patients using ondansetron. Avoid ondansetron in patients with congenital long QT syndrome. ECG monitoring is recommended in patients with electrolyte abnormalities (e.g., hypokalemia or hypomagnesemia), congestive heart failure, bradyarrhythmias, or patients taking other medicinal products that lead to QT prolongation.
Masking of Progressive Ileus and Gastric Distension
The use of ondansetron in patients following abdominal surgery or in patients with chemotherapy-induced nausea and vomiting may mask a progressive ileus and gastric distention.
Effect on Peristalsis
Ondansetron is not a drug that stimulates gastric or intestinal peristalsis. It should not be used instead of nasogastric suction.
Storage:
Store at 20° and 25°C (68° and 77°F). See USP controlled room temperature. Protect from light.